Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902588 | 0.94 | CYP1A2 (0.53) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL21052403 | 0.92 | MAPT (0.53) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL13734761 | 0.92 | MAPT (0.53) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL31264375 | 0.92 | MAPT (0.53) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL101402 | 0.87 | — | — | |
| SCHEMBL21645058 | 0.84 | CYP1A2 (0.44) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL19362798 | 0.82 | DGKA (0.55) | ALDH1A1TSHRTDP1CNR1CNR2 | |
| SCHEMBL10011030 | 0.82 | L3MBTL1 (0.58) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL10012032 | 0.82 | GSTP1 (0.56) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL1702581 | 0.81 | CYP1A2 (0.57) | CYP1A2GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4720051-A1 | IONIZABLE LIPIDS | Bristol-Myers Squibb Company (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240390284-A1 | IONIZABLE LIPIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024243480-A1 | IONIZABLE LIPIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-3720431-B1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-10-30 | — | — | EP | disclosed |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2024-03-12 | — | — | US | disclosed |
| US-20210177794-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2021-06-17 | — | — | US | disclosed |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-25 | — | — | US | disclosed |
| EP-3720431-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2020-10-14 | — | — | EP | disclosed |
| CN-111712240-A | Fatty acid derivatives for the treatment of non-alcoholic steatohepatitis | 巴斯夫股份公司 | 2020-09-25 | — | — | CN | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2019111048-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2019-06-13 | — | — | WO | disclosed |
| US-20190023645-A1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE PARIS-SUD (FR) | 2019-01-24 | — | — | US | disclosed |
| CN-103827272-A | Low sulfur fuel compositions having improved lubricity | BUTAMAX TM ADVANCED BIOFUELS | 2014-05-28 | — | — | CN | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177794-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H3, NR1H2 | CYP1A2 182/4885GAA 1055/4885MGAM 2940/4885 |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H2, NR1H3 | CYP1A2 178/4885GAA 1063/4885MGAM 2971/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | CYP1A2 2840/4885GAA 3633/4885MGAM 4547/4885 |
| US-20190023645-A1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | HDAC6, HDAC1, HDAC5 | CYP1A2 2883/4885GAA 291/4885MGAM 2538/4885 |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H2, NR1H3 | CYP1A2 178/4885GAA 1063/4885MGAM 2971/4885 |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | HDAC6, HDAC1, HDAC5 | CYP1A2 2916/4885GAA 447/4885MGAM 2736/4885 |
| US-20080045596-A1 | Ep2 Receptor Agonists | PTGER2, PTGER1, PTGER3 | CYP1A2 315/4885GAA 4742/4885MGAM 4254/4885 |
| US-20240390284-A1 | IONIZABLE LIPIDS | NPC1L1, ABCB4, NPC1 | CYP1A2 4833/4885GAA 660/4885MGAM 2770/4885 |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H3, NR1H2 | CYP1A2 182/4885GAA 1055/4885MGAM 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.